Treatment of cancer pain: Special considerations in patients with renal disease

American Journal of Cancer

Volumn 3, Issue 4, 2004, Pages 247-256

  Schug, Stephan A ^a,b   Morgan, Jennifer ^b  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b ROYAL PERTH HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALFENTANIL; ANALGESIC AGENT; ANTICONVULSIVE AGENT; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CYCLOOXYGENASE 2 INHIBITOR; FENTANYL; GABAPENTIN; HYDROMORPHONE; KETAMINE; METHADONE; MORPHINE DERIVATIVE; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE DERIVATIVE; OXYCODONE; PARACETAMOL; REMIFENTANIL; SUFENTANIL; TRAMADOL; TRICYCLIC ANTIDEPRESSANT AGENT;

ALLODYNIA; CANCER PAIN; COGNITIVE DEFECT; COMORBIDITY; DRUG ACTIVITY; DRUG CHOICE; DRUG EFFICACY; DRUG METABOLISM; HUMAN; KIDNEY DISEASE; KIDNEY FAILURE; MYOCLONUS; NAUSEA; PRIORITY JOURNAL; PRURITUS; PSYCHOLOGICAL ASPECT; QUALITY OF LIFE; RESPIRATION DEPRESSION; REVIEW; SEDATION; SIDE EFFECT; SYMPTOMATOLOGY; TREATMENT OUTCOME; TREATMENT PLANNING;

EID: 10044260845     PISSN: 11756357     EISSN: None     Source Type: Journal    
DOI: 10.2165/00024669-200403040-00004     Document Type: Review

References (91)

1. Daut RL, Cleeland CS. The prevalence and severity of pain in cancer. Cancer 1982; 50(9): 1913-8
2. Abraham JL. Management of pain and spinal cord compression in patients with advanced cancer. Ann Intern Med 1999; 131 (1): q 37-45
3. Benedetti C, Brock C, Cleeland C, et al. NCCN practice guidelines for cancer pain. Oncology 2000; 14 (11A): 135-50
4. Management of cancer pain: adults. Cancer Pain Guideline Panel. Agency for Health Care Policy and Research. Am Fam Physician 1994; 49 (8): 1853-68
5. Walser M. Assessing renal function from creatinine measurements in adults with chronic renal failure. Am J Kidney Dis 1998 Jul; 32 (1): 23-31
6. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41
7. Kintzel PE. Anticancer drug-induced kidney disorders. Drug Saf 2001; 24 (1): 19-38
8. Flombaum CD. Metabolic emergencies in the cancer patient. Semin Oncol 2000; 27 (3): 322-234
9. Davidson TG. Conventional treatment of hypercalcemia of malignancy. Am J Health Syst Pharm 2001; 58 Suppl. 3: S8-15
10. Clark AD, Shetty A, Soutar R. Renal failure and multiple myeloma: pathogenesis and treatment of renal failure and management of underlying myeloma. Blood Rev 1999; 13 (2): 79-90
11. Russo P. Urological emergencies in the cancer patient. Semin Oncol 2000; 27 (3): 288-97
12. World Health Organization. Cancer pain management. Geneva: WHO, 1986
13. Working Group of the Ethical Issues in Medicine Committee of the Royal College of Physicians. Principles of pain control in palliative care for adults. Guidance prepared by a Working Group of the Ethical Issues in Medicine Committee of the Royal College of Physicians. J R Coll Physicians Lond 2000 Jul/Aug; 34 (4): 350-2
14. Hanks GW, Conno F, Cherny N, et al. Morphine and alternative opioids in cancer pain: the EAPC recommendations. Br J Cancer 2001; 84 (5): 587-93
15. Fillastre JP, Singlas E. Pharmacokinetics of newer drugs in patients with renal impairment. Clin Pharmacokinet 1991; 20 (4): 293-310
16. Lam YW, Banerji S, Hatfield C, et al. Principles of drug administration in renal insufficiency. Clin Pharmacokinet 1997 Jan; 32 (1): 30-57
17. Touchette MA, Slaughter RL. The effect of renal failure on hepatic drug clearance. DICP 1991; 25 (11): 1214-24
18. Reetze-Bonorden P, Bohler J, Keller E. Drug dosage in patients during continuous renal replacement therapy. Clin Pharmacokinet 1993; 24 (5): 362-79
19. Portenoy RK. Treatment of temporal variations in chronic cancer pain. Semin Oncol 1997; 24 (16): 7-12
20. Mercadante S, Sapio M, Caligara M, et al. Opioid sparing effect of diclofenac in cancer pain. J Pain Symptom Manage 1997; 14: 15-20
21. Choi L, Johnson CA. Removal of drugs by hemodialysis and peritoneal dialysis. Dial Transplant 1987; 16 (10): 538-9
22. Clive DM, Stoff JS. Renal syndromes associated with nonsteroidal antiinflammatory drugs. N Engl J Med 1984; 310 (9): 563-72
23. Ravnskov U. Glomerular, tubular and interstitial nephritis associated with nonsteroidal antiinflammatory drugs: evidence of a common mechanism. Br J Clin Pharmacol 1999; 47 (2): 203-10
24. CSI prescribing group TAC: SIpg. Considerations for the safe prescribing and use of COX-2-specific inhibitors. Med J Aust 2002; 176 (7): 328-31
25. Brezin JH, Katz SM, Schwartz AB, et al. Reversible renal failure and nephrotic syndrome associated with nonsteroidal anti-inflammatory drugs. N Engl J Med 1979; 301 (23): 1271-3
26. McQuay HJ. Opioids in pain management. Lancet 1999; 353: 2229-32
27. Osborne RJ, Joel S, Trew D, et al. Analgesic activity of morphine-6-glucuronide [letter]. Lancet 1988; I: 828
28. D'Honneur G, Gilton A, Sandouk P, et al. Plasma and cerebrospinal fluid concentrations of morphine and morphine glucuronides after oral morphine: the influence of renal failure. Anesthesiology 1994; 81: 87-93
29. Aitkenhead AR, Vater M, Achola K, et al. Pharmacokinetics of single dose IV morphine in normal volunteers and patients with end-stage renal failure. Br J Anaesth 1984; 56 (8): 813-9
30. Regnard CFB, Twycross RG. Metabolism of narcotics [letter]. BMJ 1984; 288: 260
31. McQuay HJ, Moore RA. Be aware of renal function when prescribing morphine. Lancet 1984; II: 284-5
32. Chan GL, Matzke GR. Effects of renal insufficiency on the pharmacokinetics and pharmacodynamics of opioid analgesics. Drug Intell Clin Pharm 1987; 21 (10): 773-83
33. Sarhill N, Walsh D, Nelson KA. Hydromorphone: pharmacology and clinical applications in cancer patients. Support Care Cancer 2001; 9 (2): 84-96
34. Hagen N, Thirlwell MP, Dhaliwal HS, et al. Steady-state pharmacokinetics of hydromorphone and hydromorphone-3-glucuronide in cancer patients after immediate and controlled-release hydromorphone. J Clin Pharmacol 1995; 35 (1): 37-44
35. Zheng M, McErlane KM, Ong MC. Hydromorphone metabolites: isolation and identification from pooled urine samples of a cancer patient. Xenobiotica 2002; 32 (5): 427-39
36. Smith MT. Neuroexcitatory effects of morphine and hydromorphone: evidence implicating the 3-glucuronide metabolites. Clin Exp Pharmacol Physiol 2000; 27 (7): 524-8
37. Lee MA, Leng ME, Tiernan EJ. Retrospective study of the use of hydromorphone in palliative care patients with normal and abnormal urea and creatinine. Palliat Med 2001; 15 (1): 26-34
38. Babul N, Darke AC, Hagen N. Hydromorphone metabolite accumulation in renal failure. J Pain Symptom Manage 1995; 10 (3): 184-6
39. Fainsinger R, Schoeller T, Boiskin M, et al. Palliative care round: cognitive failure and coma after renal failure in a patient receiving captopril and hydromorphone. J Palliat Care 1993; 9 (1): 53-5
40. Nugent M, Davis C, Brooks D, et al. Long-term observations of patients receiving transdermal fentanyl after a randomised trial. J Pain Symptom Manage 2001; 21 (5): 385-91
41. Mystakidou K, Befon S, Kouskouni E, et al. From codeine to transdermal fentanyl for cancer pain control: a safety and efficacy clinical trial. Anticancer Res 2001; 21 (3C): 2225-30
42. Coluzzi PH, Schwartzberg L, Conroy JD, et al. Breakthrough cancer pain: a randomized trial comparing oral transmucosal fentanyl citrate (OTFC) and morphine sulfate immediate release (MSIR). Pain 2001; 91 (1-2): 123-30
43. Hunt R, Fazekas B, Thorne D, et al. A comparison of subcutaneous morphine and fentanyl in hospice cancer patients. J Pain Symptom Manage 1999; 18 (2): 111-9
44. Moffit EA, Scovil JE, Barker RA, et al. Myocardial metabolism and haemodynamic responses during high-dose fentanyl anaesthesia for coronary patients. Can Anaesth Soc J 1984; 31 (6): 611-8
45. Hudson RJ, Thomson IR, Cannon JE, et al. Pharmacokinetics of fentanyl in patients undergoing abdominal aortic surgery. Anesthesiology 1986; 64 (3): 334-8
46. Corall IM, Moore AR, Strunin L. Plasma concentrations of fentanyl in normal surgical patients and those with severe renal and hepatic disease [abstract]. Br J Anaesth 1980; 52: 101P
47. Koehntop DE, Rodman JH. Fentanyl pharmacokinetics in patients undergoing renal transplantation. Pharmacotherapy 1997; 17 (4): 746-52
48. Davies G, Kingswood C, Street M. Pharmacokinetics of opioids in renal dysfunction. Clin Pharmacokinet 1996; 31 (6): 410-22
49. Raffa RB, Friderichs E, Reimann W, et al. Opioid and nonopioid components independently contribute to the mechanism of action of tramadol, an 'atypical' opioid analgesic. J Pharmacol Exp Ther 1992; 260 (1): 275-85
50. Wilder-Smith CH, Bettiga A. The analgesic tramadol has minimal effect on gastrointestinal molor function. Br J Clin Pharmacol 1997; 43 (1): 71-5
51. Osipova NA, Novikov GA, Beresnev VA, et al. Analgesic effect of tramadol in cancer patients with chronic pain: a comparison with prolonged action morphine sulfate. Curr Ther Res 1991; 50 (6): 812-21
52. Wilder-Smith CH, Schimke J, Osterwalder B, et al. Oral tramadol, a mu-opioid agonist and monoamine reuptake-blocker, and morphine for strong cancer-related pain. Ann Oncol 1994; 5 (2): 141-6
53. Paar WD, Poche S, Gerloff J, et al. Polymorphic CYP2D6 mediates O-demethylation of the opioid analgesic tramadol. Eur J Clin Pharmacol 1997; 53 (3-4): 235-9
54. Bamigbade TA, Davidson C, Langford RM, et al. Actions of tramadol, its enantiomers and principle metabolite, O-desmethyltramadol, on serotonin (5-HT) efflux and uptake in the rat dorsal raphe nucleus. Br J Anaesth 1997; 79: 352-6
55. Radbruch L, Grond S, Lehmann KA. A risk-benefit assessment of tramadol in the management of pain. Drug Saf 1996; 15(1): 8-29
56. Wilder-Smith CH, Hill L, Osier W, et al. Effect of tramadol and morphine on pain and gastrointestinal motor function in patients with chronic pancreatitis. Dig Dis Sci 1999; 44 (6): 1107-16
57. Lintz W. Pharmacokinetics of tramadol and its metabolite M1 in patients with impaired renal function and in those undergoing hemodialysis or other artificial blood purification processes. Aachen: Gruenenthal GmbH, 1990
58. Barnung SK, Treschow M, Borgbjerg FM. Respiratory depression following oral tramadol in a patient with impaired renal function. Pain 1997; 71 (1): 111-2
59. Ross FB, Smith MT. The intrinsic antinociceptive effects of oxycodone appear to be kappa-opioid receptor mediated. Pain 1997; 73 (2): 151-7
60. Rischitelli DG, Karbowicz SH. Safety and efficacy of controlled-release oxycodone: a systematic literature review. Pharmacotherapy 2002; 22 (7): 898-904
61. Heiskanen TE, Ruismaki PM, Seppala TA, et al. Morphine or oxycodone in cancer pain? Acta Oncol 2000; 39 (8): 941-7
62. Kirvela M, Lindgren L, Seppala T, et al. The pharmacokinetics of oxycodone in uremic patients undergoing renal transplantion. J Clin Anesth 1996; 8: 13-8
63. Kaiko RF, Benziger DP, Cheng C, et al. Clinical pharmacokinetics of controlled release oxycodone in renal impairment [abstract]. Clin Pharmacol Ther 1996; 59: 130
64. Sawe J. High-dose morphine and methadone in cancer patients. Clinical pharmacokinetic considerations of oral treatment. Clin Pharmacokinet 1986; 11 (2): 87-106
65. Inturrisi CE, Colburn WA, Kaiko RF, et al. Pharmacokinetics and pharmacodynamics of methadone in patients with chronic pain. Clin Pharmacol Ther 1987; 41 (4): 392-401
66. Kreek MJ, Scheeler AJ, Gutjahr CL, et al. Methadone use in patients with chronic renal disease. Drug Alcohol Depend 1980; 5 (3): 197-205
67. Mercadante S, Lodi F, Sapio M. Long-term ketamine subcutaneous continuous infusion in neuropathic cancer pain. J Pain Symptom Manage 1995; 10: 564-8
68. Lauretti GR, Lima IC, Reis MP, et al. Oral ketamine and transdermal nitroglycerin as analgesic adjuvants to oral morphine therapy for cancer pain management. Anesthesiology 1999; 90 (6): 1528-33
69. Wieber J, Gugler R, Hengstmann JH, et al. Pharmacokinetics of ketamine in man. Anaesthesist 1975; 24 (6): 260-3
70. Koppel C, Arndt I, Ibe K. Effects of enzyme induction, renal and cardiac function on ketamine plasma kinetics in patients with ketamine long-term analgosedation. Eur J Drug Metab Pharmacokinet 1990; 15 (3): 259-63
71. Schmid RL, Sandier AN, Katz J. Use and efficacy of low-dose ketamine in the management of acute postoperative pain: a review of current techniques and outcomes. Pain 1999; 82 (2): 111-25
72. Fishbain D. Evidence-based data on pain relief with antidepressants. Ann Med 2000; 32 (5): 305-16
73. Bryson HM, Wilde MI. Amitriptyline: a review of its pharmacological properties and therapeutic use in chronic pain states. Drugs Aging 1996; 8 (6): 459-76
74. Lieberman JA, Cooper TB, Suckow RF, et al. Tricyclic antidepressant and metabolite levels in chronic renal failure. Clin Pharmacol Ther 1985; 37 (3): 301-7
75. Wiffen P, Collins S, McQuay H, et al. Anticonvulsant drugs for acute and chronic pain. Cochrane Database Syst Rev 2000 (3): CD001133
76. Swerdlow M, Cundill JG. Anticonvulsant drugs used in the treatment of lancinating pain: a comparison. Anaesthesia 1981; 36 (12): 1129-32
77. Eckhardt K, Ammon S, Hofmann U, et al. Gabapentin enhances the analgesic effect of morphine in healthy volunteers. Anesth Analg 2001; 91 (1): 185-91
78. Wong MO, Eldon MA, Keane WF, et al. Disposition of gabapentin in anuric subjects on hemodialysis. J Clin Pharmacol 1995; 35 (6): 622-6
79. Blum RA, Comstock TJ, Sica DA, et al. Pharmacokinetics of gabapentin in subjects with various degrees of renal function. Clin Pharmacol Ther 1994; 56 (2): 154-9
80. Jones H, Aguila E, Farber HW. Gabapentin toxicity requiring intubation in a patient receiving long-term hemodialysis [case report]. Ann Intern Med 2002; 137(1): 74
81. Coleman RE, Rubens RD. The clinical course of bone metastases from breast cancer. Br J Cancer 1987; 55 (1): 61-6
82. Mercadantes S. Melignant bone pain: pathophysiology and treatment. Pain 1997; 69: 1-18
83. Mercadante S. Malignant bone pain: pathophysiology and treatment. Pain 1997; 69: 1-18
84. Robertson AG, Reed NS, Ralston SH. Effect of oral clodronate on metastatic bone pain: a double blind, placebo-controlled study. J Clin Oncol 1995; 13: 2427-30
85. British Association of Surgical Oncology Guidelines. The management of metastatic bone disease in the United Kingdom: the Breast Specialty Group of the British Association of Surgical Oncology. Eur J Surg Oncol 1999; 25 (1): 3-23
86. Fleisch H. Biphosphonates: pharmacology and use in the treatment of tumour induced hypercalcaemic and metastatic bone disease. Drugs 1991; 42 (6): 919-44
87. Body J. Dosing regimens and main adverse events of biphosphonates. Semin Oncol 2001; 28 (4Suppl. 11): 49-53
88. Turk DC, Sist TC, Okifuji A, et al. Adaptation to metastatic cancer pain, regional/local cancer pain and non-cancer pain: role of psychological and behavioral factors. Pain 1998; 74 (2-3): 247-56
89. Thomas EM, Weiss SM. Nonpharmacological interventions with chronic cancer pain in adults. Cancer Control 2000; 7 (2): 157-64
90. Rimer B, Levy MH, Keintz MK, et al. Enhancing cancer pain control regimens through patient education. Patient Educ Couns 1987; 10 (3): 267-77
91. de Wit R, van Dam F, Zandbelt L, et al. A pain education program for chronic cancer pain patients: follow up results from a randomised controlled trial. Pain 1997; 73: 55-69